スニチニブ
参考資料

1 2 3 4 5 6  “Sutent- sunitinib malate capsule”. DailyMed. 7 April 2021閲覧。
↑  “FDA approves new treatment for gastrointestinal and kidney cancer”.   U.S. Food and Drug Administration (FDA) (2006年). 2006年2月3日時点のオリジナルよりアーカイブ。2021年12月3日閲覧。
↑  “スーテントカプセル12.5mg インタビューフォーム”. 2021年12月3日閲覧。
↑  スーテントカプセル12.5mg、日経メディカル
↑  “スーテントカプセル12.5mg 添付文書”. www.info.pmda.go.jp. 2021年12月4日閲覧。
1 2 3 4 5 6 7 8 9 10  “Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial”. Lancet 368 (9544):  1329–1338. (2006). doi:10.1016/S0140-6736(06)69446-4. PMID 17046465.
1 2 3  “Sunitinib versus interferon alfa in metastatic renal-cell carcinoma”. N Engl J Med 356 (2):  115–124. (2007). doi:10.1056/NEJMoa065044. PMID 17215529.
↑  “Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.”. Southern Medical Journal 100 (3):  328–330. (2007-03-01). doi:10.1097/smj.0b013e31802f01a9. PMID 17396743. http://www.thefreelibrary.com/Yellow+skin+discoloration+associated+with+sorafenib+use+for+treatment...-a0161610873.
↑  Alexandrescu, DT; McClure, R; Farzanmehr, H; Dasanu, CA (2008). “Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib”. Journal of Clinical Oncology 26 (24):  4047–8. doi:10.1200/jco.2008.18.3525. PMID 18711201.
↑  “Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules.”. J Urol 191 (3):  611–618. (March 2014). doi:10.1016/j.juro.2013.08.090. PMC 4015627. PMID 24018239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015627/.
↑  “Overall survival with sunitinib versus interferon alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC). Abstract no. 5024.”. Presented at ASCO 2008. Available at: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32895.
↑  “Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma”. J. Clin. Oncol. 27 (22):  3584–90. (August 2009). doi:10.1200/JCO.2008.20.1293. PMC 3646307. PMID 19487381. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646307/.
↑  Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. | CureHunter
↑  95％信頼区間
↑  “Pfizer Scores New Approval for Sutent in Europe”. (2 Dec 2010). http://www.genengnews.com/gen-news-highlights/pfizer-scores-new-approval-for-sutent-in-europe/81244326/
↑  FDA approves Sutent for rare type of pancreatic cancer
↑  "Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma"
↑  “Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition”. Arch Dermatol 144 (11):  1525–6. (November 2008). doi:10.1001/archderm.144.11.1525. PMID 19015436.  オリジナルの2011-07-25時点におけるアーカイブ。. https://web.archive.org/web/20110725002034/http://archderm.ama-assn.org/cgi/content/full/144/11/1525.
↑  “Gastrointestinal stromal tumor: a clinical overview”. Hematol. Oncol. Clin. North Am. 23 (1):  69–78, viii. (February 2009). doi:10.1016/j.hoc.2008.11.006. PMID 19248971.
↑  “Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations”. Expert Rev Anticancer Ther 9 (6):  831–8. (June 2009). doi:10.1586/era.09.34. PMID 19496720.
↑  “Sunitinib in solid tumors”. Expert Opin Investig Drugs 18 (6):  821–34. (June 2009). doi:10.1517/13543780902980171. PMID 19453268.
↑  “Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability”. J Mol Med (Berl) 89 (6):  595–602. (Jun 2011). doi:10.1007/s00109-011-0737-3. PMID 21331509.
↑  “Phase II study of SU11248, a multi-targeted tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer”. Presented at ASCO 2005. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31881.
↑  “Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial”. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24 (18S (June 20 suppl)). (2006). Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=34252.
↑  “A Phase 2 Study to Evaluate the Efficacy of SU11248 in Patients with Unresectable Neuroendocrine Tumors”. Presented at ASCO 2005. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=33268.
↑  “In Gene Sequencing Treatment for Leukemia, Glimpses of the Future”. 2021年12月3日閲覧。
↑  Writer, GEN Staff (2011年5月23日). “FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors” (英語). GEN - Genetic Engineering and Biotechnology News. 2021年12月5日閲覧。